Methods and systems for identification and prioritization of mutation-derived neoantigens
US12331361B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 31, 2019 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Apr 19, 2044 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70539
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.